Special Issue

The Role of Long Non-coding RNA in Solid Tumors

Message from the Guest Editors

Long non-coding RNAs (lncRNAs) are a class of highly conserved and tissue-specific, non-protein-coding RNAs longer than 200 nucleotides functioning in the posttranscriptional regulation of gene expression. LncRNAs may target multiple RNAs, and this ensures a high degree of stage- and state-specific modulation. Thus, these RNAs exert profound effects on homeostatic adaptation processes, in both physiological and pathological conditions. LncRNAs have recently been emerging as important modulators of cancer phenotype, becoming invaluable tools for both biomarker discovery and mechanistic studies of cancer. Key modules of tumor or initiation and progression, ranging from the acquisition of pro-metastatic features to metabolic reprogramming and chemoresistance, are among the functions of this growing family of molecules. This Topic Issue is focused on all aspects of the dynamic roles lncRNAs play in cancer progression by mediating adaptive response to stress and by fueling intratumoral heterogeneity, in response to internal and external clues. In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Guest Editors

Dr. Sabrina Strano
Regina Elena National Cancer Institute, Rome, Italy

Dr. Mario Cioce
Department of Medicine, University Campus Bio-Medico of Rome, Rome, Italy

Deadline for manuscript submissions

closed (31 October 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed

mdpi.com/si/119946

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)